Preclinical Study on Aerosolized Interferon-α1b for RSV Treatment

Aerosolized human interferon-α1b demonstrated antiviral activity against respiratory syncytial virus with an in vitro EC₅₀ of 4.64 ng/mL. The dataset, authored by Mingming Yang and last updated in April 2026, contains a study document describing efficacy in mice and pharmacokinetics in monkeys. In the mouse model, the treatment reduced lung viral titers more than ribavirin under the tested conditions.

Use Cases

• Analyze the dose-dependent reduction of lung viral titers in mice based on the described animal model results
• Compare the systemic bioavailability and lung-targeted exposure of an inhaled drug based on the pharmacokinetic data from cynomolgus monkeys
• Evaluate the safety profile of repeated aerosol dosing based on the reported minimal to mild lung inflammation findings

Strengths

• Report includes specific efficacy metrics, such as an in vitro EC₅₀ of 4.64 ng/mL and a systemic bioavailability of 3.33% in monkeys.
• Study compares treatment efficacy against a standard antiviral (ribavirin) and reports statistical significance (p < 0.001).
• Safety assessment includes detailed grading of observed inflammation (Grade 1 to 2) and notes its reversibility.

Limitations

• Dataset is a single 11.2 KB DOCX file, indicating very limited scope and likely a summary document rather than raw experimental data.
• Row count and column-level documentation are absent; data structure and variable semantics must be inferred from the text.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains results from in vitro assays, animal model experiments, and pharmacokinetic/toxicology studies as described.

Freshness

Last updated 2026-04-30 05:40:07; freshness should be verified.